COPD
BioAffinity Aims to Make Lung Cancer Test Available Nationally Following Pathology Lab Acquisition
Premium
With the acquisition of Precision Pathology Services, BioAffinity plans on expanding the availability of the CyPath Lung LDT nationwide next year.
In a bid to expand recognition and treatment of alpha-1 antitrypsin deficiency, a cause of COPD, Grifols is making its over-the-counter genetic test available for free.
The breath-based biopsy firm is collaborating with Renji Hospital to conduct a clinical trial into the early detection of lung cancer in China.
The drug-device combination measures activity of live organisms by detecting metabolites, and can be used to indicate virulence and guide treatment.
The firm is taking its in-home monitoring systems for COPD and cystic fibrosis, and its professional-use sepsis confirmation system through clinical trials.